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Abstract
Background: Oxidative stress is a widely seen phenomenon in several carcinomas. Increasing evidence also suggests
that it has a significant role in the development of epithelial ovarian carcinoma (EOC). 8-Hydroxydeoxyguanosine
(8-OHdG) is one of the main indicators of oxidative stress and increased expression of 8-OHdG has previously been seen
in EOC. DJ-1 is an oncoprotein connected to oxidative stress regulation, but its role in ovarian cancer is not well known.
We investigated redox status in different histotypes of EOC by measuring serum 8-OHdG and DJ-1 concentrations and
their associations with known prognostic factors.
Methods: Serum samples from newly diagnosed EOC patients were collected in 1996–2009 and stored at the
Department of Obstetrics and Gynecology, Oulu University Hospital. Serum 8-OHdG and DJ-1 levels were measured by
using commercially available ELISA kits. Clinical data was gathered retrospectively from the patients` files. Results were
analyzed by using SPSS software.
Results: In total, 112 patient samples were analyzed (38 serous, 20 mucinous, 34 endometrioid and 20 clear-cell).
High serum 8-OHdG levels were associated with poor overall survival (OS) (p = 0.019), poor disease-free survival (DFS)
(p = 0.020), platinum resistance (p = 0.002), serous histology versus other (p = 0.033), stage III–IV versus I–II (p = 0.009)
and suboptimal surgical outcome (p = 0.012). Regarding histotypes, in the endometrioid EOC group in particular, serum
8-OHdG levels were significantly associated with poor DFS (p = 0.005), suboptimal surgical outcome (p = 0.025), and
platinum resistance (p = 0.007). The prognostic significance of 8-OHdG in patients with endometrioid cancer in terms of
DFS was confirmed in Cox regression analysis. High DJ-1 levels were associated with high histological grade (p = 0.029)
and nonsignificantly associated with serous histology vs. other histology (p = 0.089).
Conclusions: An elevated serum 8-OHdG level is a significant predictor of poor prognosis, especially in cases of the
endometrioid subtype of ovarian carcinoma. High 8-OHdG levels are associated with all traditional factors of poor
prognosis in ovarian cancer and they also predict earlier development of platinum resistance. These results could be
valuable when deciding the primary treatment mode for EOC patients.
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Background
Ovarian cancer is the seventh most common cancer
worldwide and one of the main causes of cancer-related
death. Usually it is diagnosed at an advanced stage when
the prognosis is poor. In most cases relapse occurs within
two years, the patient becomes chemoresistant and five-
year survival is only 45 % at best. The known risk factors
of ovarian cancer are infertility, family history, smoking
and hormone replacement therapy, but the main reasons
for the occurrence of ovarian cancer are still unclear. In
recent years many studies have shown the role of oxidative
stress in the development of ovarian and other cancers.
Evidence suggests that ovulation increases the levels of
inflammatory agents, which can further lead to muta-
tions in DNA [1–4]. Ovulation creates a void on the
ovarian surface, which leads to the wound-healing
process, with increased levels of inflammatory mediators
and reactive oxygen species (ROS) [1–3]. It has been
suggested that cancer cells from the fallopian tubes, the
cervix or endometriotic lesions migrate to the ovaries
and form tumors near the corpus luteum [5].
Reactive oxygen species are formed either from incom-
plete reduction of oxygen during cellular respiration, or
following exposure to external agents such as ultraviolet
light, ionizing radiation or redox-state-modifying drugs,
which are factors known to be connected with carcino-
genesis [6]. Because of their unpaired electrons, ROS
molecules are very unstable and react easily with other
molecules. They can interact directly with DNA and
they can oxidize lipids and proteins, generating interme-
diates that react with DNA, a cascade with the potential
to cause DNA mutations when antioxidant defenses are
overwhelmed [6]. The hydroxyl radical (•OH) is ex-
tremely unstable and reacts rapidly with other mole-
cules. When it attacks DNA, 8-hydroxydeoxyguanosine
(8-OHdG) can be formed. Tissue expression of 8-OHdG
and its serum concentrations are associated with the
prognosis of several carcinomas, including ovarian can-
cer, breast cancer, colorectal cancer, cutaneous melan-
oma, non-small-cell lung cancer, diffuse large B-cell
lymphoma and esophageal cancer [7–13]. In colorectal
carcinomas, immunohistochemical expression levels of
8-OHdG and nitrotyrosine are significantly higher in
malignant tissues compared with adenomas or non-
tumorous tissues of the colon [14, 15].
The redox-regulated multifunctional protein DJ-1 is in-
volved in diverse cell processes such as chemotaxis, cell
migration, cell adhesion, angiogenesis, apoptosis, cell–
extracellular matrix interactions and immune regulation
[16]. It protects cells from oxidative stress, detoxifies re-
active oxygen species and is converted into a variant with
a more acidic isoelectric point [16]. Overexpression of DJ-
1 increases the chemoresistance of neoplastic cells by inhi-
biting apoptotic pathways [16, 17]. It has been associated
with early-onset parkinsonism [18], hence its other name
PARK7, and it is overexpressed in several malignant tu-
mors including breast, lung, glottic and esophageal carcin-
omas [19–22]. Increased serum DJ-1 levels have been
reported in patients with metastatic uveal melanoma, pan-
creatic cancer and endometrioid-type endometrial cancers
(EECs) [23–25].
We have previously reported that high serum and
tumor tissue levels of 8-OHdG in epithelial ovarian car-
cinoma (EOC) patients are associated with traditional
factors of poor prognosis and also with serous histology
[26]. In this previous study, 75 % of patients had serous
histology and we were therefore unable to assess the
prognostic value in different histological subtypes. We
included 35 patients from the previous study to the
current study (32 serous, 2 endometrioid and 1 clear cell
histology) aiming to evaluate the roles of serum 8-
OHdG and DJ-1 as prognostic factors in different histo-
logical types of epithelial ovarian cancer.
Methods
The study involved 112 epithelial ovarian cancer patients
diagnosed and treated at Oulu University Hospital in
1996–2009. In most cases, the patients were operated
upon at Oulu University Hospital. In some cases the pri-
mary operation was in the central hospital, as the tumor
was assumed to be benign. In those cases, the staging
operation was carried out at Oulu University Hospital.
Operations were categorized as optimal if no macro-
scopic tumor remained and suboptimal if there was any
residual tumor. After the operation, the patients under-
went taxane- and platinum-based chemotherapy for a
total of six treatments at three-week intervals. If the pa-
tients showed a complete response after chemotherapy,
they were transferred to a routine follow-up program.
The patient data was retrospectively collected from the
archives. Age, histology, grade, stage, optimality of the
operation, resistance to platinum-based chemotherapy,
disease-free survival (DFS) and overall survival (OS) were
recorded (Table 1). Recurrence was diagnosed according
to radiological RECIST 1.1 criteria [27]. Platinum resist-
ance was defined as progression during platinum treat-
ment or recurrence < 6 months after the last platinum
dose. Overall survival was calculated as the time from
diagnosis to the time of death.
Serum samples were collected from every patient the
day before the operation or at the time of diagnosis and
the samples were stored at −70 °C until use. Commercial
ELISA kits for assay of 8-OHdG (JaICA, Japan) and DJ-1
(Nordic BioSite, Sweden) were used. The assays were
carried out by following the manufacturers’ instructions,
except that sample filtering was omitted.
The data was analyzed by using IBM SPSS Statistics for
Windows 21.0.0.0 software. The significance of associations
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was assessed by using the Mann–Whitney U test and the
Kruskal–Wallis test. In survival analysis, serum concen-
trations were re-formatted as two-class variables using
the median level as a cut-off point. Survival was ana-
lyzed by using Kaplan–Meier curves and the log-rank
test. Cox multivariate regression analysis was used for
multivariate analysis. Probability values < 0.05 were
considered significant.
This study was approved by the National Supervisory
Authority for Welfare and Health (1339/05.01.00.06/2009)
and The Regional Ethics Committee of the Northern
Ostrobothnia Hospital District (53/2008).
Results
Correlation with traditional EOC risk factors
Serum levels of 8-OHdG were determined in 105 samples
and the mean concentration was 3.22 ng/ml (95 % CI
2.73–3.71 ng/ml). The median 8-OHdG concentration
was 2.53 ng/ml and this cut-off level was applied in
Kaplan–Meier analysis. The mean concentration of DJ-1
(n = 48) was 15.99 ng/ml (95 % CI 12.2–19.8 ng/ml), the
median being 10.5 ng/ml. A high level of 8-OHdG was as-
sociated with serous histology vs. other types (p = 0.033),
platinum resistance (p = 0.002), stage III–IV versus I–II
(p = 0.009) and a suboptimal surgical outcome (p = 0.012)
(Fig. 1, Table 2). Among the patients with endometrioid
histology, a high serum 8-OHdG level was associated with
platinum resistance (p = 0.007) and a suboptimal surgical
outcome (p = 0.025).
High DJ-1 levels were significantly associated with a
high histological grade (p = 0.029) and non-significantly
associated with serous histology versus other histology
(p = 0.089). No associations between levels of 8-OHdG
and the stage of the disease, or 8-OHdG and DJ-1 levels
were found.
Survival analysis
Higher 8-OHdG concentrations were associated with
poor DFS (p = 0.020) as well as with poor OS (p = 0.019)
in the whole study group (Fig. 2). In cases of endome-
trioid histology, serum 8-OHdG levels were highly sig-
nificantly associated with DFS (p = 0.005).
In Cox regression analysis a high level of serum 8-
OHdG in the patients with endometrioid histology was a
more significant predictor of poor DFS (OR 1.387; 95 %
CI 1.095–1.758; p = 0.007) than a suboptimal surgical re-
sult (OR 2.898; 95 % CI 0.925–9.076; p = 0.068), high stage
(OR 1.221; 95 % CI 0.215–6.915, p = 0.822) or high histo-
logical grade (OR 1.566; 95 % CI 0.259–9.457, p = 0.625).
Discussion
We report here that the preoperative serum concentra-
tion of 8-OHdG is a highly significant prognostic marker
in cases of EOC, especially in endometrioid ovarian car-
cinomas. On the other hand, serum DJ-1 levels seem not
to have prognostic significance in cases of EOC.
As one of the most studied oxidative stress markers, 8-
OHdG has been investigated by way of immunohisto-
chemistry in connection with various carcinomas, but via
serum 8-OHdG levels in only a few cancer types. The
main repair enzyme connected with 8-OHdG is (human)
8-oxoguanine DNA glycosylase 1 (hOGG1), which cleaves
damaged guanosine from DNA and thereafter it is se-
creted to extracellular fluids [28]. The existing data sug-
gest that extracellular 8-OHdG levels are not affected by
diet, cell death or artifact formation [29]. High serum 8-
OHdG levels have been recognized as a predictor of short-
term survival in non-small-cell lung cancer patients [11],
serous ovarian cancer patients [26, 30] and in children
with acute leukemia [31]. In one of our previous studies
[26] we reported that high serum 8-OHdG levels as well
as high 8-OHdG immunohistochemical expression were
Table 1 Patient characteristics
Histology
Serous 38 (33.9 %)
Mucinous 20 (17.9 %)
Endometrioid 34 (30.4 %)
Clear-cell 20 (17.9 %)
Age 22–85 (mean 59)
Stage
I–II 50 (44.6 %)
III–IV 60 (53.6 %)
Missing 2 (1.8 %)
Grade
1 22 (19.6 %)
2 17 (15.2 %)
3 71 (63.4 %)
Missing 2 (1.8 %)
Surgical Outcome
Optimal 55 (49.1 %)
Suboptimal 21 (18.8 %)
Inoperable 35 (31.3 %)
Missing 1 (0.9 %)
Platinum resistance
Yes 43 (38.4 %)
No 48 (42.9 %)
Other Reason 2 (1.8 %)
Missing 19 (17.0 %)
Recurrence
Yes 58 (51.8 %)
No 51 (45.5 %)
Missing 3 (2.7 %)
Pylväs-Eerola et al. BMC Cancer  (2015) 15:493 Page 3 of 7
associated with poor clinical outcome in cases of serous
ovarian cancer. However, that particular study was focused
mainly on serous carcinomas, serum 8-OHdG associated
to poor survival only in low grade disease, we were not
able to assess progression-free survival and prognostic sig-
nificance was not observed in multivariate analysis. On
the basis of the results, we suggested that there could be
variation in oxidative stress levels between different ovar-
ian cancer histological subtypes, and 8-OHdG levels could
possibly reflect chemoresistance – hence the current study
was undertaken.
We have previously reported higher 8-OHdG tissue
expression in borderline ovarian tumors than in benign
ones, suggesting a role of 8-OHdG in early ovarian epi-
thelial carcinogenesis [32]. Epithelial ovarian cancers can
be assigned to different groups not only by their differ-
ent histological appearances but also by their obviously
different carcinogenetic patterns. In this study serous
carcinomas were associated with the highest serum 8-
OHdG levels, but the endometrioid histotype was the
one where the most significant association between
serum 8-OHdG levels and the outcome of the disease
was observed. Some endometrioid ovarian cancers are
known to arise from atypical endometriosis. We have pre-
viously shown biochemical connections between endomet-
riosis and endometriosis-associated endometrioid cancers.
In those studies immunohistochemical 8-OHdG expres-
sion in endometrioid cancer tissue was significantly lower
than in the related endometriosis tissue [33]. This finding
suggests that at a certain phase of cancer development,
DNA guanine adducts are degraded at the tissue level and
8-OHdG is released to the serum. Thus, 8-OHdG might
be a surrogate marker of induced cancer metabolism.
One of the main findings in this study was the associ-
ation between preoperative serum 8-OHdG levels, not
only with all studied traditional prognostic factors, but
also with the earlier development of chemoresistance.
One of the most important mechanisms of action of
platinum regimens used in cases of ovarian carcinoma is
based on ROS generation. Therefore, we cannot rule out
the possibility that the association with chemoresistance
could be explained by the induction of antioxidant enzymes
in the most oxidatively stressed tumors. Our observation of
a lack of association between serum concentrations of 8-
OHdG and DJ-1 is not necessarily contradictory to this
hypothesis, since there are also DJ-1-independent redox-
regulating pathways such as Nrf2, which recently was con-
nected to platinum resistance in cases of bladder cancer
[34]. On the other hand, elevated levels of ROS may simply
generate mutations that are able to favor the survival of
some cancer cell subpopulations.
High disease burden, poor differentiation and subopti-
mal surgical outcome are well characterized prognostic
factors in all subtypes of ovarian cancer. However, an el-
evated serum 8-OHdG level was an even more powerful





















Fig. 1 Association between EOC histology and serum 8-OHdG level (p = 0.033)
Table 2 Associations between prognostic factors and serum concentrations of 8-OHdG in the whole study population, in the
endometrioid subgroup, and levels of DJ-1
Serous histology Platinum resistance Stage III–IV Inoperability Grade
High 8-OHdG 0.033 0.002 0.009 0.012 NS
High 8-OHdG NS 0.007 NS 0.025 NS
Endometrioid histology
High DJ-1 0.089 NS NS NS 0.029
Values are p-values, NS = non-significant
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endometrioid histology. Although it did not significantly
reflect OS in multivariate analysis, DFS is a valid end-
point from a clinical point of view. The median survival
time of the patients with an endometrioid histotype and
high 8-OHdG serum concentrations was 48 months,
compared with 111 months in the endometrioid ovarian
cancer patients with low 8-OHdG serum levels. In clear-
cell and mucinous cancer types the serum 8-OHdG level
was not of prognostic value in this patient cohort.
DJ-1 is an oxidative response protein with oncogenic
properties. It induces PI3K-AKT and ERK1/3 signaling,
influences c-myc expression and provides protection
from ROS-induced apoptosis in vitro [35–37]. Increased
serum DJ-1 levels have been detected in endometrioid-
type endometrial cancer (EEC) patients compared with
healthy controls [25]. In the same study, higher DJ-1
serum levels and immunohistochemical expression in the































































































Fig. 2 Kaplan–Meier curves demonstrating relationships between serum 8-OHdG concentrations and disease-free survival in the whole study
population (a), overall survival in the whole study population (b), disease-free survival in cases of carcinoma with endometrioid histology (c) and
overall survival in the endometrioid histology group (d)
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when set against the levels in cases of EEC. In ovarian can-
cer, DJ-1 levels, measured by PCR from effusions, were
more expressed at an advanced stage [38]. In gastric car-
cinoma DJ-1 plays an important role in the development
of peritoneal carcinomatosis in vitro [39] and in breast
cancer low DJ-1 immunohistochemical and FISH (fluores-
cence in situ hybridization) expression seems to predict
pathological complete remission after neoadjuvant chemo-
therapy [40]. High DJ-1 immunohistochemical expression
in pancreatic cancer is associated with chemoresistance
[24]. In prostate carcinoma tissue DJ-1 is overexpressed
compared with that in benign hyperplasia [41], and in
non-small-cell lung cancer overexpression has been de-
scribed compared with that in normal lung tissue [42]. In
the current material elevated DJ-1 concentrations were
observed in patients with high-grade EOC, but no associa-
tions with other traditional prognostic factors or survival
were found.
The present results confirm the hypothesis that differ-
ent epithelial ovarian cancer histotypes represent differ-
ent carcinogenic backgrounds and clinical behavior and
they should be categorized in more detail according to
their biomolecular characteristics. Serum concentrations
of 8-OHdG also predict the development of platinum re-
sistance and could thus assist in the choice of chemo-
therapy. This is in line with the results of our previous
clinical pilot study of biomarkers of the response to bev-
acizumab in serous ovarian cancer. In that study, immu-
nohistochemical expression of 8-OHdG appeared to
predict a longer-term response to bevacizumab treat-
ment [43].
Conclusions
An elevated serum 8-OHdG level is a highly significant
predictor of poor prognosis, especially in cases of the
endometrioid subtype of epithelial ovarian cancer. In
addition, high 8-OHdG levels predict earlier develop-
ment of platinum resistance, which may have a signifi-
cant clinical impact if confirmed in future studies. These
results could be beneficial as regards chemotherapy and
maintenance treatment in cases of ovarian cancer.
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